Clinical Trials Logo

Clinical Trial Summary

This project seeks to perform whole genome sequence (WGS) and whole transcriptome sequence (WTS) analysis on 350 patients with suspected inherited bone marrow failure syndromes and related disorder (IBMFS-RD) in order to increase the genomic diagnostic rate in IBMFS.


Clinical Trial Description

IBMFS-RD are a heterogeneous group of rare diseases resulting in significant morbidity and early mortality. These syndromes are individually and collectively rare (affecting <1 per 10,000 people) and a significant proportion are unexplained by mutations in known genes. Whilst rare, these familial conditions are also likely underdiagnosed due to their relatively recent description and also due to lack of accessible genomic testing. For patients with clinically suspected IBMFS-RD, receiving a genomic diagnosis is critical to: - Establish a precise and reliable diagnosis (including distinguishing a monogenic aetiology from more common acquired or autoimmune causes of bone marrow failure which have dramatically different treatments (e.g. immunosuppression) - Inform prognosis, clinical course, optimal treatment choice and screening for non-haematological organ dysfunction - Optimise allogeneic haematopoietic stem cell transplant (HSCT) chemotherapy conditioning and minimise regimen-related toxicity - Inform risk-benefit analysis of performing allogeneic HSCT to potentially prioritise other therapies (including novel gene therapy strategies) - Avoiding the catastrophe of HSCT donation from occult genetically affected relatives - Provide counselling (including stem cell donor counselling) and offer genetic testing for potentially affected family members - Provide accurate reproductive counselling and reproductive options to affected individuals This study aims to provide WGS and WTS to a national cohort of patients with IBMFS-RD to determine diagnostic rate, health economic impact, health implementation challenges and other exploratory endpoints. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05196789
Study type Observational
Source Peter MacCallum Cancer Centre, Australia
Contact Kelsey Man, PhD
Phone 61 3 8559 5000
Email kelsey.man@petermac.org
Status Recruiting
Phase
Start date March 18, 2022
Completion date December 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04094844 - Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation N/A
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT03918343 - Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation N/A
Completed NCT01445561 - Ultra Low Dose Interleukin-2 in Healthy Volunteers Phase 1
Recruiting NCT06148610 - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Completed NCT04168983 - Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy N/A
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Completed NCT01108159 - Integrated Whole-Genome Analysis of Hematologic Disorders
Completed NCT00800839 - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide Phase 2
Completed NCT00213239 - A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children Phase 1/Phase 2
Terminated NCT00208949 - A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF Phase 2
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Completed NCT00208962 - Allogeneic Cell Therapy for Adults With Hematologic Malignancies Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Recruiting NCT05487794 - Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis N/A
Completed NCT03611257 - Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases N/A
Completed NCT02827149 - High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT